Genmab EPCORE FL-1 Trial Data

Genmab A/S announced new data from a post-hoc subgroup analysis of its pivotal Phase 3 EPCORE FL-1 trial, evaluating epcoritamab in combination with rituximab and lenalidomide (epcoritamab + R2) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The data, presented at the European Hematology Association (EHA) 2026 Congress in Sweden — Stockholm, Sweden, demonstrated consistent and sustained efficacy benefits across various clinically relevant subgroups, including those with different Follicular Lymphoma International Prognostic Index (FLIPI) scores, progression of disease within 24 months of frontline treatment (POD24), and patient fitness levels. The analysis showed progression-free survival benefits consistently favored the epcoritamab combination, with hazard ratios below 0.3 across all major subgroups, indicating a substantially lower risk of disease progression or death compared with R2 alone. Overall response rates and complete response rates were also higher with epcoritamab plus R2, reinforcing its potential as a fixed-duration treatment for R/R follicular lymphoma, as highlighted by Benoit Tessoulin.